These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 34417529)
1. Self-sealing hyaluronic acid-coated 30-gauge intravitreal injection needles for preventing vitreous and drug reflux through needle passage. Eom Y; Kim S; Huh J; Koh MY; Hwang JY; Kang B; Li X; Lee MS; Lee H; Kim HM; Song JS Sci Rep; 2021 Aug; 11(1):16996. PubMed ID: 34417529 [TBL] [Abstract][Full Text] [Related]
2. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Roh MI; Kim HS; Song JH; Lim JB; Kwon OW Ophthalmology; 2009 Jan; 116(1):80-6. PubMed ID: 19118699 [TBL] [Abstract][Full Text] [Related]
3. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951 [TBL] [Abstract][Full Text] [Related]
4. The effect of triamcinolone acetonide or bevacizumab on the levels of proinflammatory cytokines after retinal laser photocoagulation in pigmented rabbits. Arimura S; Takamura Y; Miyake S; Gozawa M; Iwasaki K; Tomomatsu T; Matsumura T; Inatani M Exp Eye Res; 2016 Aug; 149():1-7. PubMed ID: 27296072 [TBL] [Abstract][Full Text] [Related]
5. Subconjunctival reflux and need for paracentesis after intravitreal injection of 0.1 ml bevacizumab: comparison between 27-gauge and 30-gauge needle. Lorenz K; Zwiener I; Mirshahi A Graefes Arch Clin Exp Ophthalmol; 2010 Nov; 248(11):1573-7. PubMed ID: 20730442 [TBL] [Abstract][Full Text] [Related]
7. Vitreous Reflux Frequency and Intraocular Pressure After First-Time Intravitreal Aflibercept Injections: Comparison of 30- and 32-Gauge Needles. Muto T; Machida S Clin Ophthalmol; 2020; 14():625-634. PubMed ID: 32184551 [TBL] [Abstract][Full Text] [Related]
8. Intravitreous bevacizumab injection: an experimental study in New Zealand white rabbits. Cortez RT; Ramirez G; Collet L; Thakuria P; Giuliari GP Arch Ophthalmol; 2010 Jul; 128(7):884-7. PubMed ID: 20625050 [TBL] [Abstract][Full Text] [Related]
9. Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy. Martens TF; Remaut K; Deschout H; Engbersen JF; Hennink WE; van Steenbergen MJ; Demeester J; De Smedt SC; Braeckmans K J Control Release; 2015 Mar; 202():83-92. PubMed ID: 25634806 [TBL] [Abstract][Full Text] [Related]
10. Tower microneedle minimizes vitreal reflux in intravitreal injection. Lee CY; You YS; Lee SH; Jung H Biomed Microdevices; 2013 Oct; 15(5):841-8. PubMed ID: 23666517 [TBL] [Abstract][Full Text] [Related]
11. Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy. Cancarini A; Costagliola C; Dell'omo R; Romano M; Morescalchi F; Agnifili L; Ruggeri G; Semeraro F Minerva Endocrinol; 2014 Dec; 39(4):305-11. PubMed ID: 25371057 [TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Sawada O; Kawamura H; Kakinoki M; Sawada T; Ohji M Arch Ophthalmol; 2007 Oct; 125(10):1363-6. PubMed ID: 17923544 [TBL] [Abstract][Full Text] [Related]
13. Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy. Suzuki Y; Suzuki K; Yokoi Y; Miyagawa Y; Metoki T; Nakazawa M Retina; 2014 Jan; 34(1):165-71. PubMed ID: 23851630 [TBL] [Abstract][Full Text] [Related]
15. Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection. Agawa T; Usui Y; Wakabayashi Y; Okunuki Y; Juan M; Umazume K; Kezuka T; Takeuchi M; Yamauchi Y; Goto H Retina; 2014 Sep; 34(9):1811-8. PubMed ID: 24801651 [TBL] [Abstract][Full Text] [Related]
16. Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs. Carnota-Méndez P; Méndez-Vázquez C; Otero-Villar J; Saavedra-Pazos JA Eur J Ophthalmol; 2014; 24(5):771-7. PubMed ID: 24706353 [TBL] [Abstract][Full Text] [Related]
17. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1. Sohn EH; He S; Kim LA; Salehi-Had H; Javaheri M; Spee C; Dustin L; Hinton DR; Eliott D Arch Ophthalmol; 2012 Sep; 130(9):1127-34. PubMed ID: 22965588 [TBL] [Abstract][Full Text] [Related]
18. Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. Rodrigues EB; Grumann A; Penha FM; Shiroma H; Rossi E; Meyer CH; Stefano V; Maia M; Magalhaes O; Farah ME J Ocul Pharmacol Ther; 2011 Apr; 27(2):197-203. PubMed ID: 21314588 [TBL] [Abstract][Full Text] [Related]
19. Simultaneous increase in multiple proinflammatory cytokines in the aqueous humor in neovascular glaucoma with and without intravitreal bevacizumab injection. Ohira S; Inoue T; Shobayashi K; Iwao K; Fukushima M; Tanihara H Invest Ophthalmol Vis Sci; 2015 Jun; 56(6):3541-8. PubMed ID: 26030108 [TBL] [Abstract][Full Text] [Related]
20. Validation of hyaluronic acid-agar-based hydrogels as vitreous humor mimetics for in vitro drug and particle migration evaluations. Thakur SS; Shenoy SK; Suk JS; Hanes JS; Rupenthal ID Eur J Pharm Biopharm; 2020 Mar; 148():118-125. PubMed ID: 31981693 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]